Diabetes Atherosclerosis Intervention Study (DAIS): Difference between revisions
Jump to navigation
Jump to search
Rim Halaby (talk | contribs) (Created page with "__NOTOC__ {{High density lipoprotein}} {{CMG}}; {{AE}} {{Rim}} ==Overview== The Diabetes Atherosclerosis Intervention Study (DAIS) is a double-blind placebo-controlled study...") |
Rim Halaby (talk | contribs) |
||
| Line 5: | Line 5: | ||
==Overview== | ==Overview== | ||
The Diabetes Atherosclerosis Intervention Study (DAIS) is a double-blind placebo-controlled study that assessed the cardiovascular | The Diabetes Atherosclerosis Intervention Study (DAIS) is a double-blind placebo-controlled study that assessed the rate of cardiovascular disease following the administration of 200 mg fenofibrate in non-insulin-dependent diabetes subjects. | ||
==References== | ==References== | ||
Revision as of 00:11, 19 August 2014
|
High Density Lipoprotein Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Clinical Trials |
|
Case Studies |
|
Diabetes Atherosclerosis Intervention Study (DAIS) On the Web |
|
American Roentgen Ray Society Images of Diabetes Atherosclerosis Intervention Study (DAIS) |
|
Diabetes Atherosclerosis Intervention Study (DAIS) in the news |
|
Risk calculators and risk factors for Diabetes Atherosclerosis Intervention Study (DAIS) |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Rim Halaby, M.D. [2]
Overview
The Diabetes Atherosclerosis Intervention Study (DAIS) is a double-blind placebo-controlled study that assessed the rate of cardiovascular disease following the administration of 200 mg fenofibrate in non-insulin-dependent diabetes subjects.